---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-25-008268"
form_type: "8-K"
ticker: "KAPA"
cik: "0001962011"
company_name: "Kairos Pharma, LTD."
filed_at: "2025-02-26T23:59:59+00:00"
generated_at: "2026-05-26T04:00:41.695016+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "medium"
source: SEC EDGAR
---

# Kairos Pharma presents preclinical data for KROS 101 and KROS 401 at AACR IO

## Summary
- KROS 101 (GITR agonist) inhibited tumor growth in melanoma model and increased CD4+/CD8+ T cell proliferation.
- KROS 101 prevented T cell exhaustion, a key advantage over prior GITR antibody TRX518.
- KROS 401 peptide inhibitor reduced M2 macrophages and showed anti-tumor effect in glioma-bearing mice.
- Data presented at AACR Immuno-Oncology conference in Los Angeles, February 23-26, 2025.
- CEO highlighted potential of KROS platform to address T cell exhaustion and reprogram tumor microenvironment.

## SEC filing metadata
- accession: 0001493152-25-008268
- form_type: 8-K
- ticker: KAPA
- cik: 0001962011
- company_name: Kairos Pharma, LTD.
- filed_at: 2025-02-26T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: medium
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1962011/000149315225008268/0001493152-25-008268-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1962011/000149315225008268/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-25-008268
- JSON: https://secwatch.observer/filing/0001493152-25-008268.json
- Plain text: https://secwatch.observer/filing/0001493152-25-008268.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.